



Republic of the Philippines  
Department of Health  
**Food And Drug Administration**  
Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa  
City



### Notification of Cosmetic Product

Pursuant to the existing rules and regulations of the Food and Drug Administration (FDA) for the notification of cosmetics, the product notification is hereby acknowledged,

Cosmetic Notification Number: **NN-1000007552121**  
Validity: 11 March 2024

#### Particulars of the Product

Brand Name: ECZEKLEEN AD  
Product Name: ECZEKLEEN AD ADVANCED BARRIER REPLENISHING LOTION  
Variant/s: N/A

#### Particulars of the Manufacturer

Name of the Manufacturer: ARB LABORATORIES INC.  
Address of the Manufacturer: Lot 15, North Zuzuarregui St., Old Balara, Quezon City  
Country of Manufacture: Philippines

#### Particulars of the Local Company Responsible for Placing the Product in the Market


Name of the Company: ESKEEN LABORATORIES, INC.  
Address of the Company: UG1 Star Centrum Condominiums, Gil Puyat Ave. corner Malugay St., Barangay Bel-Air, Makati, Metro Manila  
LTO Number: LTO-3000001771311

The product is allowed to be sold in the local market subject to compliance with the requirements of the ASEAN Cosmetic Directive and the FDA laws, and its implementing rules and regulations. This notification should not be taken as a guarantee and/or endorsement of the safety, quality, and claimed benefit of the product. Any subsequent changes to the information submitted in this notification will render this notification invalid and a new notification will have to be submitted.

The company hereby ensures that they shall respond and cooperate fully with the FDA with regard to any subsequent post-marketing activity initiated by the FDA. Further, the company shall be responsible for ensuring that each consignment of the product continues to meet all the legal requirements, and conforms to all the standards and specifications of the product declared to the FDA.

This authorization is subject to suspension, cancellation, or recall should any violation of FDA laws, and its implementing rules and regulations, involving the product be committed.

BY AUTHORITY OF THE ACTING DIRECTOR GENERAL

  
Engr. Ana Trinidad F. Rivera, MSc  
Director IV, Center for Cosmetic Regulation and Research